Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949351 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL14599843 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL411121 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL14599844 | 0.85 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL12052490 | 0.85 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL12052508 | 0.85 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL12296033 | 0.83 | CHRM2 (0.35) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL4602108 | 0.76 | SLC18A3 (0.40) | SLC18A3 | |
| SCHEMBL4602773 | 0.76 | SLC18A3 (0.40) | SLC18A3 | |
| SCHEMBL444081 | 0.74 | SLC18A3 (0.41) | SLC18A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344162-B2 | Synthetic processes for the preparation of aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20120271057-A9 | SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120065408-A1 | SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2012-03-15 | — | — | US | disclosed |
| US-8080673-B2 | Synthetic processes for the preparation of aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2011-12-20 | — | — | US | disclosed |
| US-20100217014-A1 | SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7754897-B2 | Synthetic processes for the preparation of aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065408-A1 | SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS | CYP2D6, CYP3A43, CYP2F1 | CHRM2 327/4885CHRM1 481/4885CHRM4 763/4885 |
| US-20100217014-A1 | SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS | CYP2D6, CYP3A43, CYP2F1 | CHRM2 327/4885CHRM1 481/4885CHRM4 763/4885 |
| US-20120271057-A9 | SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS | CYP2D6, CYP3A43, CYP2F1 | CHRM2 327/4885CHRM1 481/4885CHRM4 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.